Should we routinely add CRP to clozapine titrations? - Learning from three cases

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Psychiatry

Background:

• An international guideline offers personalized clozapine titration schedules based on DNA ancestry, sex-smoking status, and clozapine poor metabolizer (PM) status.
• Monitoring C-reactive protein (CRP) levels during the initial 4 weeks of clozapine therapy is recommended.

Observation:

• Three patient cases are re-examined to illustrate potential benefits of the guideline.
• Case 1 involved a Chinese male clozapine PM with underlying inflammation.
• Cases 2 and 3 involved patients who developed myocarditis during clozapine titration, with Case 2 having multiple risk factors.

Findings:

• Applying the guideline could have prevented adverse outcomes by adjusting titration based on individual risk factors and CRP levels.
• The guideline might have prevented clozapine initiation in Case 1 due to abnormal CRP.
• Slow titration for clozapine PMs and early identification of genetic PM status via CRP were highlighted.

Implications:

• Elevated CRP during clozapine titration suggests patient-specific inflammation due to rapid titration or concurrent infection.
• Prospective studies are needed to validate the association between CRP changes and clozapine-induced inflammation or infection.
• Personalized clozapine titration strategies incorporating pharmacogenomic and inflammatory markers can enhance patient safety.